Loading...
The optimal preoperative therapy for adenocarcinoma of the esophagus or gastroesophageal junction (GEJ) remains controversial. Standard options include preoperative or perioperative chemotherapy, or combined chemotherapy and radiation therapy followed by surgery.
In the phase 3, multicenter, European NEO-AEGIS trial, patients with operable adenocarcinoma of the esophagus or GEJ and endoscopic ultrasound stage T2–3, N0–3, M0 disease were randomized to perioperative chemotherapy (3 preoperative and 3 postoperative cycles of epirubicin, cisplatin or oxaliplatin, and capecitabine or continuous 5-FU infusion) or preoperative combined chemoradiotherapy (weekly carboplatin and paclitaxel and 41.4 Gy of radiotherapy in 23 fractions). Patients were r…